Skip to main content


A phase 3 clinical trial evaluating the efficacy of extended-release injectable risperidone for patients with schizophrenia showed a statistically significant delay in time to relapse, compared to the placebo.
Take our quick quiz to see if you know which psychosocial interventions are recommended for patients with schizophrenia.
The use of CYP2D6 and CYP2C19 genotyping to guide antipsychotic prescribing did not improve drug persistence in patients with schizophrenia, according to a randomized clinical trial published online in JAMA Network Open.
Take our quiz to test your knowledge of the burden and impact of schizophrenia, including the average potential life lost to the disease, co-occurring mental and behavioral health disorders, and an increased rate of suicide.
The National Institute of Mental Health (NIMH) has awarded a $52 million, 5-year grant for a study focused on understanding the trajectory toward schizophrenia in high-risk youth.
What does in utero malnutrition have to do with schizophrenia? And why is weight gain, a problematic adverse event, also linked with clinical effectiveness of antipsychotic medications?
Why do so many antipsychotic medications induce symptoms, signs, and physiologic changes that are already present to a lesser degree in the disease states that they are intended to treat?
Back to Top